Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baxdrostat ADME Study in Healthy Males
NCT05961384Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of baxdrostat in hypertension (HTN), sponsored by AstraZeneca. Primary endpoints: Total radioactivity recovery in urine and feces, Area under the curve [AUC] of baxdrostat and CIN-107M and 4 more. Started Nov 2021; status: completed.
02
Drugs
baxdrostat
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT05961384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05961384.